Roivant Sciences is a biopharmaceutical company focused on advancing innovative treatments for various diseases through a unique model that emphasizes the development of underutilized compounds and technologies
The company aims to accelerate the drug development process by leveraging a network of subsidiaries, each dedicated to specific therapeutic areas, including neurology, immunology, and rare diseases. By fostering collaboration and employing a data-driven approach, Roivant seeks to bring effective therapies to patients more efficiently and enhance the overall landscape of healthcare.
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while awaiting further clarity on trade policie
President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2 billion.
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments.
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure rates and positive secondary endpoints. Roivant authorizes a $1.5 billion share repurchase program
